What is the efficacy of andexanet alfa as an anticoagulation reversal agent for deep venous thrombosis (DVT)?

Updated: Jun 05, 2019
  • Author: Kaushal (Kevin) Patel, MD; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
  • Print

Andexanet alfa is a recombinant, modified FXa molecule that acts as a decoy protein that is catalytically inactive but has a high affinity for FXa inhibitors. It is being developed as an antidote for apixaban, edoxaban, and ribaroxaban. Andexanet alfa has been shown to reverse the anticoagulant effects of apixaban and rivroxaban in human volunteers, and more studies are ongoing. [152]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!